In vivo imaging methods, particularly translocator protein positron emission tomography (TSPO-PET) and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), have advanced our understanding of glial activation and BBB permeability in conditions such as Alzheimer’s disease, Parkinson’s disease, epilepsy, multiple sclerosis, Huntington’s disease, schizophrenia, and depression. Here, TSPO is linked to Huntington disease.